BAY 3547926 / Bayer - LARVOL DELTA

BAY 3547926: Novel targeted radionuclide therapy for hepatocellular carcinoma (AACR 2025) - P1 | "BANTAM-01 (NCT06764316) is a multicenter, open label, non-randomized study to evaluate the safety and tolerability, PK, and anti-tumor activity of 225Ac-GPC3 alone and in combination. The study is now active and enrolling GPC3 positive HCC patients."

IO biomarker • Hepatocellular Cancer • Oncology • Solid Tumor • AFP • GPC3

Bayer Initiates Phase I Study Targeting GPC3 With Actinium-225 Radiopharmaceutical in Patients With Advanced Hepatocellular Carcinoma (Businesswire) - "Bayer announced today initiation of a Phase I clinical trial with 225Ac-GPC3 (BAY 3547926), an investigational targeted alpha radiopharmaceutical being developed to treat tumors expressing Glypican-3 (GPC3) in patients with advanced hepatocellular carcinoma (HCC)....The first-in-human, dose escalation study (NCT06764316) will evaluate the safety, tolerability and preliminary efficacy of BAY 3547926 alone, and as a combination therapy in patients with advanced HCC."

Trial status • Hepatocellular Cancer

A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer (clinicaltrials.gov) - P1 | N=148 | Recruiting | Sponsor: Bayer | Not yet recruiting ➔ Recruiting

Enrollment open • Hepatocellular Cancer • Hepatology • Liver Cancer • Oncology • Solid Tumor

A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer (clinicaltrials.gov) - P1 | N=148 | Not yet recruiting | Sponsor: Bayer | Trial completion date: Feb 2029 ➔ Dec 2033 | Trial primary completion date: Nov 2027 ➔ Jul 2030

Trial completion date • Trial primary completion date • Hepatocellular Cancer • Hepatology • Liver Cancer • Oncology • Solid Tumor